top of page

Nanobiotix's CEO explains how his company is trying to boost the efficacy of radiation therapy

Jul 27, 2023
1 min read

Laurent Levy talks about his company’s nanoparticle technology, a recent deal with Janssen, and the state of European biotech.

https://vimeo.com/849116653

Recent Posts

Cambridge, UK based Microbiotica announced results from a phase 1b trial of its microbiome treatment MB310 in ulcerative colitis showing a 63% remission rate

Cambridge, UK based Microbiotica announced results from a phase 1b trial of its microbiome treatment MB310 in ulcerative colitis showing a 63% remission rate

Ocular Therapeutix Chair & CEO Pravin Dugel discusses the result of today's SOL-1 phase 3 superiority trial of AXPAXLI vs EYLEA in wet AMD

Ocular Therapeutix Chair & CEO Pravin Dugel discusses the result of today's SOL-1 phase 3 superiority trial of AXPAXLI vs EYLEA in wet AMD

Oxford based Infinitopes raised an additional $15.4M in a second closing of its seed round to bring the total raised to $35.1M. It will have clinical data on its cancer vaccine by the end of the year

Oxford based Infinitopes raised an additional $15.4M in a second closing of its seed round to bring the total raised to $35.1M. It will have clinical data on its cancer vaccine by the end of the year

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page